On August 20, GENSCRIPT BIO surged 14.65% in regular trading, reaching 32.8 HKD/share with turnover of 643 million HKD, extending a multi-day rally driven by strong interim results and successive broker upgrades.

On the news front, JPMorgan raised its target price to 35 HKD while maintaining an Overweight rating, following CICC's 78.8% target price increase to 32 HKD and Huatai Securities' Buy rating with a 36.08 HKD target. The company's H1 results significantly exceeded expectations, with revenue rising 27.3% YoY to $404.2 million on a comparable basis. The life sciences segment delivered adjusted operating profit of $94 million, up 102.8% YoY, driven by surging AIDD-related demand which doubled YoY for the third consecutive half-year period. Adjusted net profit reached $62.5 million, representing 203.3% YoY growth. CICC noted that AIDD is catalyzing robust life sciences growth and improving operational efficiency, while the broader HK-listed pharma sector is experiencing valuation recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)